A passion for outthinking cancer
Eric, Associate Director at Merrimack
Our collaborations

Innovation doesn’t happen alone.
Learn more about teaming with Merrimack.

Learn more


View all news
October 19, 2018

Merrimack Discontinues Phase 2 SHERLOC Study of MM-121 in Patients with Non-Small Cell Lung Cancer Due to Futility

Read more
September 20, 2018

Merrimack Receives $5 Million Milestone Payment from Shire

Read more
September 06, 2018

Merrimack Completes Enrollment in Randomized Phase 2 SHERLOC Study of MM-121 (seribantumab) in Non-Small Cell Lung Cancer (NSCLC)

Read more
August 07, 2018

Merrimack Reports Second Quarter 2018 Financial Results

Read more

Social Media

Follow us on Twitter

October 8, 2018
We are taking a systematic approach to our preclinical development work. Learn more about our pipeline here: http://wwZRfyJQ2f

October 5, 2018
Our pipeline is shaped by understanding cancer pathways, treatments designed with pharmacological properties to mat… http://XYlHtTVLHu